428 related articles for article (PubMed ID: 16800840)
1. The impact of genotype on endocrine complications in thalassaemia major.
Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in the prevalence and severity of bone disease in thalassaemia.
Kyriakou A; Savva SC; Savvides I; Pangalou E; Ioannou YS; Christou S; Skordis N
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():116-22. PubMed ID: 19337164
[TBL] [Abstract][Full Text] [Related]
3. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
Gamberini MR; De Sanctis V; Gilli G
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
[TBL] [Abstract][Full Text] [Related]
4. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
[TBL] [Abstract][Full Text] [Related]
5. Endocrine complications in patients with Thalassaemia Major.
Toumba M; Sergis A; Kanaris C; Skordis N
Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
[TBL] [Abstract][Full Text] [Related]
6. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
[TBL] [Abstract][Full Text] [Related]
7. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
8. The impact of iron overload and genotype on gonadal function in women with thalassaemia major.
Skordis N; Gourni M; Kanaris C; Toumba M; Kleanthous M; Karatzia N; Pavlides N; Angastiniotis M
Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():292-5. PubMed ID: 16462714
[TBL] [Abstract][Full Text] [Related]
9. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
[TBL] [Abstract][Full Text] [Related]
10. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
[TBL] [Abstract][Full Text] [Related]
12. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
13. Low bone mineral density in adolescents with beta-thalassemia.
Vogiatzi MG; Autio KA; Mait JE; Schneider R; Lesser M; Giardina PJ
Ann N Y Acad Sci; 2005; 1054():462-6. PubMed ID: 16339698
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.
Belhoul KM; Bakir ML; Kadhim AM; Dewedar HE; Eldin MS; Alkhaja FA
Ann Saudi Med; 2013; 33(1):18-21. PubMed ID: 23458935
[TBL] [Abstract][Full Text] [Related]
15. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major.
Ang AL; Tzoulis P; Prescott E; Davis BA; Barnard M; Shah FT
Eur J Haematol; 2014 Mar; 92(3):229-36. PubMed ID: 24164584
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis in beta-thalassemia: Clinical and genetic aspects.
Origa R; Fiumana E; Gamberini MR; Armari S; Mottes M; Sangalli A; Paglietti E; Galanello R; Borgna-Pignatti C
Ann N Y Acad Sci; 2005; 1054():451-6. PubMed ID: 16339696
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
Wu KH; Chang JG; Ho YJ; Wu SF; Peng CT
Hemoglobin; 2006; 30(2):251-6. PubMed ID: 16798650
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
Liang Y; Bajoria R; Jiang Y; Su H; Pan H; Xia N; Chatterjee R; Lai Y
Trop Med Int Health; 2017 Jun; 22(6):716-724. PubMed ID: 28544032
[TBL] [Abstract][Full Text] [Related]
19. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
Galanello R
Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]